| Followers | 1131 |
| Posts | 32852 |
| Boards Moderated | 3 |
| Alias Born | 01/11/2016 |
Thursday, April 02, 2020 5:17:22 PM
LGND is the common and the Z is the warrants, if I am not mistaken if I am, I saw one of the docs over 200 dollars, by 2023 so essentially if this gets over 200 dollars, the warrants should realistically trade over 20 dollars to par up at 10%, but being conservative I would say anything between 2-5 dollars is given for the fact that the warrants are trading on OTC.
Recent LGND News
- Ligand to Participate in June Investor Conferences • GlobeNewswire Inc. • 05/27/2026 08:01:00 PM
- Orchestra BioMed Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates • GlobeNewswire Inc. • 05/12/2026 08:18:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2026 11:03:45 AM
- Ligand Reports First Quarter 2026 Financial Results • GlobeNewswire Inc. • 05/07/2026 11:00:00 AM
- Orchestra BioMed Receives $15 Million Investment from Ligand Under Previously Announced Strategic Financing Agreement • GlobeNewswire Inc. • 05/06/2026 12:01:00 PM
- Ligand to Participate in May Investor Conferences • GlobeNewswire Inc. • 05/05/2026 08:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/05/2026 12:20:10 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/01/2026 08:16:45 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/30/2026 08:41:14 PM
- Rowley Law PLLC is Investigating Proposed Acquisition of XOMA Royalty Corporation • PR Newswire (US) • 04/27/2026 07:06:00 PM
- Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator • GlobeNewswire Inc. • 04/27/2026 11:00:00 AM
- Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator • GlobeNewswire Inc. • 04/27/2026 11:00:00 AM
- Ligand to Report First Quarter 2026 Financial Results on May 7, 2026 • GlobeNewswire Inc. • 04/22/2026 11:00:00 AM
- Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan) in FSGS • GlobeNewswire Inc. • 04/14/2026 11:00:00 AM
- Ligand Advances Strategic Growth with Expanded and Strengthened Business Development Team • GlobeNewswire Inc. • 03/26/2026 11:00:00 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/23/2026 08:04:37 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/11/2026 08:42:01 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2026 11:51:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2026 11:49:54 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/06/2026 09:17:26 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2026 02:04:25 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/04/2026 09:44:24 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/04/2026 09:39:12 PM
- Ligand to Participate in March Investor Conferences • GlobeNewswire Inc. • 03/04/2026 12:00:00 PM
- Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers • Edgar (US Regulatory) • 02/27/2026 10:23:30 PM
